Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2025)
Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

Industry: Biotechnology
F
Biotech is Zen Rated F and is the 139th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Zen Rating
Growth
Market Cap
Revenue
EBITDA
Earnings
EPS
Rev. Y/Y
Rev. 5Y
Earn. Y/Y
Earn. 5Y
Earnings Date
PBYI
PUMA BIOTECHNOLOGY INC
$171.25M$232.71M$54.66M$38.07M$0.772.68%0.73%133.33%N/A2025-07-31
EXEL
EXELIXIS INC
$12.43B$2.30B$894.63M$643.57M$2.2524.49%18.61%251.56%18.57%2025-08-12
AUPH
AURINIA PHARMACEUTICALS INC
$1.22B$247.30M$65.88M$39.85M$0.2929.20%278.58%N/AN/A2025-07-31
RIGL
RIGEL PHARMACEUTICALS INC
$345.83M$203.08M$48.45M$37.18M$2.1068.74%14.67%N/AN/A
ZVRA
ZEVRA THERAPEUTICS INC
$699.35M$40.59M-$60.30M-$91.99M-$1.9246.47%22.15%N/AN/A2025-08-19
HALO
HALOZYME THERAPEUTICS INC
$7.10B$1.08B$704.60M$485.36M$3.8525.65%45.83%57.14%N/A2025-08-12
PTCT
PTC THERAPEUTICS INC
$3.92B$1.77B$846.90M$594.84M$7.5691.12%40.69%N/AN/A2025-07-31
NAGE
NIAGEN BIOSCIENCE INC
$886.95M$107.93M$16.04M$14.11M$0.1829.77%16.36%N/AN/A
CRMD
CORMEDIX INC
$770.49M$82.55M$17.67M$17.18M$0.26N/A235.70%N/AN/A2025-08-07
CPRX
CATALYST PHARMACEUTICALS INC
$2.64B$534.65M$296.55M$197.35M$1.6529.97%35.05%175.00%31.48%2025-08-06
BMRN
BIOMARIN PHARMACEUTICAL INC
$11.17B$2.95B$777.43M$523.88M$2.7519.36%10.32%152.29%33.85%2025-08-05
INCY
INCYTE CORP
$13.55B$4.41B$406.83M$21.27M$0.2917.13%14.63%-91.29%N/A2025-07-28
BCRX
BIOCRYST PHARMACEUTICALS INC
$1.87B$503.49M$47.59M-$53.47M-$0.2641.67%60.16%N/AN/A2025-07-31
AKBA
AKEBIA THERAPEUTICS INC
$1.04B$184.91M$10.87M-$45.31M-$0.22-1.24%-12.02%N/AN/A2025-07-31
CSBR
CHAMPIONS ONCOLOGY INC
$110.20M$58.59M$8.10M$6.43M$0.4719.03%13.51%N/AN/A2025-07-17
HRMY
HARMONY BIOSCIENCES HOLDINGS INC
$1.99B$744.85M$237.95M$152.72M$2.6720.62%N/A13.62%N/A2025-08-12
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
$2.10B$481.17M-$1.55M-$16.95M-$0.2459.45%N/AN/AN/A2025-07-29
ALNY
ALNYLAM PHARMACEUTICALS INC
$41.17B$2.35B-$164.54M-$269.70M-$2.0917.21%52.37%N/AN/A2025-07-30
IMCR
IMMUNOCORE HOLDINGS PLC
$1.77B$333.58M$1.93M-$21.63M-$0.4325.75%N/AN/AN/A2025-08-06
BDTX
BLACK DIAMOND THERAPEUTICS INC
$167.18M$70.00M$5.44M$5.09M$0.08N/AN/AN/AN/A2025-08-12
INVA
INNOVIVA INC
$1.23B$369.84M$14.61M-$59.72M-$0.9518.70%5.39%N/AN/A2025-07-30
NVO
NOVO NORDISK A S
$307.82B$46.00B$23.12B$15.87B$3.5724.47%18.77%18.06%22.09%2025-08-06
PLX
PROTALIX BIOTHERAPEUTICS INC
$113.04M$59.76M$7.16M$3.91M$0.050.18%-1.94%-50.00%N/A2025-08-18
FENC
FENNEC PHARMACEUTICALS INC
$242.77M$30.91M-$11.14M-$14.44M-$0.53-31.23%N/AN/AN/A2025-08-07
ARWR
ARROWHEAD PHARMACEUTICALS INC
$2.57B$545.21M-$57.42M-$143.97M-$1.361,436.97%31.44%N/AN/A2025-08-11
XLO
XILIO THERAPEUTICS INC
$38.32M$9.27M-$52.61M-$54.30M-$0.82N/AN/AN/AN/A2025-08-06
HRTX
HERON THERAPEUTICS INC
$323.43M$148.52M-$2.95M-$7.79M-$0.0512.43%1.22%N/AN/A2025-08-12
MDXG
MIMEDX GROUP INC
$1.00B$352.38M$63.32M$40.18M$0.275.34%3.66%-48.08%N/A2025-07-29
IMAB
I-MAB
$174.71M$0.00N/A-$7.58M-$0.12-100.00%N/AN/AN/A2025-09-02
ONC
BEONE MEDICINES LTD
$27.24B$4.18B-$126.93M-$392.37M-$0.2951.16%59.66%N/AN/A
XOMA
XOMA ROYALTY CORP
$332.20M$42.91M$3.33M-$5.60M-$1.10638.41%31.19%N/AN/A2025-08-06
ZYME
ZYMEWORKS INC
$930.27M$93.38M-$94.99M-$113.68M-$1.5085.05%29.25%N/AN/A
KROS
KEROS THERAPEUTICS INC
$591.77M$214.71M$17.92M$4.21M-$0.1291,657.69%95.60%N/AN/A2025-07-31
TBPH
THERAVANCE BIOPHARMA INC
$573.52M$65.27M-$39.82M-$58.33M-$1.186.11%-5.79%N/AN/A2025-08-04
RPRX
ROYALTY PHARMA PLC
$20.38B$2.26B$1.34B$1.09B$2.471.13%3.78%37.99%N/A2025-08-06
ZLAB
ZAI LAB LTD
$3.72B$418.33M-$227.62M-$252.07M-$2.4043.72%N/AN/AN/A2025-08-11
STOK
STOKE THERAPEUTICS INC
$658.44M$190.91M$42.86M$50.27M$0.852,333.50%N/AN/AN/A2025-08-11
GMAB
GENMAB A
$14.21B$3.15BN/A$1.11B$1.7325.31%31.74%46.37%27.07%2025-08-07
ARGX
ARGENX SE
$34.10B$4.73M$114.32M$905.48M$15.13-88.53%-44.77%N/AN/A2025-07-15
ATRA
ATARA BIOTHERAPEUTICS INC
$55.44M$199.73M$7.38M-$15.64M-$2.57475.53%N/AN/AN/A
MNKD
MANNKIND CORP
$1.22B$297.60M$82.59M$30.12M$0.1032.50%36.93%150.00%N/A2025-08-06
VCYT
VERACYTE INC
$2.09B$463.39M$63.03M$33.05M$0.4323.42%30.60%N/AN/A2025-07-30
XERS
XERIS BIOPHARMA HOLDINGS INC
$871.24M$222.55M-$4.34M-$45.08M-$0.3029.88%120.58%N/AN/A2025-08-06
VRTX
VERTEX PHARMACEUTICALS INC
$121.30B$11.10B-$74.90M-$988.90M-$3.828.98%18.16%N/AN/A2025-07-30
ARQT
ARCUTIS BIOTHERAPEUTICS INC
$1.90B$212.82M-$100.65M-$129.72M-$1.03100.03%N/AN/AN/A2025-08-13
UTHR
UNITED THERAPEUTICS CORP
$13.43B$2.99B$1.68B$1.21B$27.0819.85%15.73%21.11%17.60%2025-07-29
TECH
BIO-TECHNE CORP
$8.25B$1.21B$289.57M$131.67M$0.834.72%9.88%-34.65%-7.46%2025-08-12
TGTX
TG THERAPEUTICS INC
$6.18B$386.39M$70.41M$39.15M$0.2733.54%379.77%-6.90%N/A2025-08-05
ACAD
ACADIA PHARMACEUTICALS INC
$3.66B$996.28M$278.16M$228.88M$1.3822.42%22.16%N/AN/A2025-07-30
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
$1.75B$189.53M-$106.35M-$141.84M-$0.958.61%15.22%N/AN/A2025-07-30
MDGL
MADRIGAL PHARMACEUTICALS INC
$7.10B$317.38M-$376.50M-$391.59M-$17.93N/AN/AN/AN/A2025-08-06
WHWK
WHITEHAWK THERAPEUTICS INC
$96.57M$27.78M$28.33M$27.61M$0.1616.51%N/AN/AN/A
CORT
CORCEPT THERAPEUTICS INC
$7.72B$685.45M$110.98M$132.49M$1.2730.93%15.40%10.43%6.66%2025-07-28
LGND
LIGAND PHARMACEUTICALS INC
$2.45B$181.49M-$119.89M-$132.62M-$7.2053.40%10.54%N/AN/A2025-08-11
CTMX
CYTOMX THERAPEUTICS INC
$192.68M$147.56M$47.70M$41.60M$0.4923.81%25.71%145.00%N/A2025-08-07
NVAX
NOVAVAX INC
$1.13B$1.25B$554.90M$478.70M$3.0325.92%133.56%N/AN/A2025-08-06
MIRM
MIRUM PHARMACEUTICALS INC
$2.64B$379.25M-$35.81M-$77.34M-$1.6169.31%N/AN/AN/A2025-07-31
CADL
CANDEL THERAPEUTICS INC
$322.16M$0.00-$36.56M-$39.58M-$1.31N/AN/AN/AN/A2025-09-03
AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$3.15B$134.15M-$32.47M-$55.46M-$0.73329.06%N/AN/AN/A2025-07-17
SPRO
SPERO THERAPEUTICS INC
$147.60M$44.58M-$69.76M-$69.76M-$1.28-59.83%29.74%N/AN/A2025-08-07
SEER
SEER INC
$125.39M$15.31M-$79.33M-$85.87M-$1.41-2.33%N/AN/AN/A2025-08-07
IPSC
CENTURY THERAPEUTICS INC
$51.70M$114.90M-$8.40M-$21.95M-$0.298,286.79%N/AN/AN/A2025-08-07
RGNX
REGENXBIO INC
$436.40M$156.72M-$122.44M-$157.69M-$3.1080.70%24.69%N/AN/A2025-07-30
ACOG
ALPHA COGNITION INC
$168.69M$2.93M-$11.47M-$11.64M-$1.30N/AN/AN/AN/A
SEPN
SEPTERNA INC
$535.15MN/AN/AN/AN/AN/AN/AN/AN/A2025-09-03
FHTX
FOGHORN THERAPEUTICS INC
$327.76M$23.50M-$71.61M-$80.44M-$1.36-30.66%N/AN/AN/A2025-08-12
MESO
MESOBLAST LTD
$1.29B$5.67MN/A-$103.35M-$0.93-24.07%-24.07%N/AN/A2025-08-27
TVTX
TRAVERE THERAPEUTICS INC
$1.50B$273.53M-$169.03M-$226.71M-$2.7975.65%8.31%N/AN/A2025-07-30
MCRB
SERES THERAPEUTICS INC
$129.68M$0.00$90.27M$72.95M$8.76-100.00%-100.00%N/AN/A2025-08-05
GLUE
MONTE ROSA THERAPEUTICS INC
$323.54M$159.49M$17.73M$6.15M$0.0814,889.38%N/AN/AN/A2025-08-07
TSHA
TAYSHA GENE THERAPIES INC
$566.71M$7.22M-$84.24M-$86.77M-$0.34-48.97%N/AN/AN/A2025-08-18
TARS
TARSUS PHARMACEUTICALS INC
$1.74B$233.67M-$93.78M-$104.94M-$2.72449.03%N/AN/AN/A2025-08-07
ACIU
AC IMMUNE SA
$208.85M$34.51M-$60.62M-$63.52M-$0.6391.20%-8.33%N/AN/A2025-08-06
AGEN
AGENUS INC
$187.26M$99.52M-$76.47M-$190.81M-$8.57-38.34%3.14%N/AN/A
ASND
ASCENDIS PHARMA A
$10.61B$418.98M-$194.68M-$388.26M-$6.6512.06%104.09%N/AN/A2025-09-09
KYMR
KYMERA THERAPEUTICS INC
$2.92B$58.89M-$232.67M-$240.88M-$3.11-25.85%N/AN/AN/A2025-08-01
FOLD
AMICUS THERAPEUTICS INC
$1.92B$543.14M$53.63M-$29.37M-$0.0928.25%21.08%N/AN/A2025-07-31
NTRB
NUTRIBAND INC
$89.68M$2.40M-$9.65M-$9.97M-$0.9018.92%51.92%N/AN/A
FTRE
FORTREA HOLDINGS INC
$450.90M$2.69B-$577.60M-$790.40M-$8.79-4.45%N/AN/AN/A2025-08-18
GYRE
GYRE THERAPEUTICS INC
$713.50M$100.64M$13.36M$7.25M$0.08-13.01%43.80%N/AN/A2025-08-19
KRYS
KRYSTAL BIOTECH INC
$4.35B$333.45M$144.76M$123.96M$4.32247.53%N/A118.18%N/A2025-08-11
ATAI
ATAI LIFE SCIENCES NV
$544.92M$1.86M-$144.77M-$148.99M-$0.91572.56%N/AN/AN/A2025-08-18
TLX
TELIX PHARMACEUTICALS LTD
$5.21B$492.58M$58.49M$31.40MN/A42.30%N/AN/AN/A2025-08-20
FULC
FULCRUM THERAPEUTICS INC
$426.44M$80.00M$957.00k-$510.00k-$0.013,087.25%154.45%N/AN/A2025-08-06
HLVX
HILLEVAX INC
$108.81M$0.00-$100.93M-$106.50M-$2.16N/AN/AN/AN/A2025-08-07
AEON
AEON BIOPHARMA INC
$9.44M$0.00$169.21M$169.12M$297.46N/AN/AN/AN/A
VRCA
VERRICA PHARMACEUTICALS INC
$75.38M$7.18M-$55.56M-$65.99M-$1.14-19.45%N/AN/AN/A2025-08-12
ANIX
ANIXA BIOSCIENCES INC
$103.08M$0.00-$12.10M-$12.13M-$0.38N/AN/AN/AN/A2025-09-12
LEGN
LEGEND BIOTECH CORP
$7.26B$728.30M-$153.44M-$218.15M-$1.20112.46%63.96%N/AN/A2025-08-29
ARVN
ARVINAS INC
$574.44M$426.90M-$39.80M-$46.60M-$0.66498.74%56.67%N/AN/A2025-07-28
CNTA
CENTESSA PHARMACEUTICALS PLC
$2.02B$15.00M-$208.73M-$223.85M-$1.88118.88%N/AN/AN/A2025-08-18
ERAS
ERASCA INC
$413.60M$0.00-$153.97M-$157.60M-$0.60N/AN/AN/AN/A2025-08-07
ASMB
ASSEMBLY BIOSCIENCES INC
$143.89M$0.00-$39.46M-$39.92M-$6.23N/A-100.00%N/AN/A
LCTX
LINEAGE CELL THERAPEUTICS INC
$244.34M$9.56M-$15.61M-$16.21M-$0.0819.42%25.25%N/AN/A2025-08-07
SLS
SELLAS LIFE SCIENCES GROUP INC
$197.56M$0.00-$26.56M-$27.13M-$0.38N/AN/AN/AN/A2025-08-07
MBIO
MUSTANG BIO INC
$10.59M$0.00-$10.54M-$10.71M-$27.12N/AN/AN/AN/A
CDTX
CIDARA THERAPEUTICS INC
$717.49M$302.00k-$181.59M-$182.98M-$26.09-98.33%-58.12%N/AN/A
ABVC
ABVC BIOPHARMA INC
$58.87M$508.38k-$1.24M-$1.81M-$0.131,904.43%N/AN/AN/A
ADCT
ADC THERAPEUTICS SA
$332.25M$75.82M-$96.50M-$149.84M-$1.4310.49%107.69%N/AN/A2025-08-12
TVRD
TVARDI THERAPEUTICS INC
$279.24M$7.57M-$35.47M-$45.08M-$30.01-55.30%-20.34%N/AN/A2025-08-12

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Jul 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

1. Puma Biotechnology (NASDAQ:PBYI)


Puma Biotechnology (NASDAQ:PBYI) is the #1 top biotech stock out of 647 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Puma Biotechnology (NASDAQ:PBYI) is: Value: A, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.

Puma Biotechnology (NASDAQ:PBYI) has a Due Diligence Score of 49, which is 26 points higher than the biotech industry average of 23.

PBYI passed 16 out of 33 due diligence checks and has strong fundamentals. Puma Biotechnology has seen its stock lose -5.74% over the past year, overperforming other biotech stocks by 64 percentage points.

Puma Biotechnology has an average 1 year price target of $7.00, an upside of 102.9% from Puma Biotechnology's current stock price of $3.45.

Puma Biotechnology stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Puma Biotechnology, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Exelixis (NASDAQ:EXEL)


Exelixis (NASDAQ:EXEL) is the #2 top biotech stock out of 647 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Exelixis (NASDAQ:EXEL) is: Value: A, Growth: C, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: B.

Exelixis (NASDAQ:EXEL) has a Due Diligence Score of 60, which is 37 points higher than the biotech industry average of 23.

EXEL passed 20 out of 33 due diligence checks and has strong fundamentals. Exelixis has seen its stock return 102.13% over the past year, overperforming other biotech stocks by 172 percentage points.

Exelixis has an average 1 year price target of $45.13, a downside of -0.98% from Exelixis's current stock price of $45.58.

Exelixis stock has a consensus Buy recommendation according to Wall Street analysts. Of the 15 analysts covering Exelixis, 40% have issued a Strong Buy rating, 20% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Aurinia Pharmaceuticals (NASDAQ:AUPH)


Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #3 top biotech stock out of 647 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 62, which is 39 points higher than the biotech industry average of 23.

AUPH passed 20 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 59.44% over the past year, overperforming other biotech stocks by 129 percentage points.

What are the biotech stocks with highest dividends?

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Dominari Holdings (NASDAQ:DOMH)


Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 5.98%, which is 4 percentage points higher than the biotech industry average of 1.58%.

Dominari Holdings's dividend payout ratio of -7.1% indicates that its high dividend yield might not be sustainable for the long-term.

2. Novo Nordisk (Ozempic) (NYSE:NVO)


Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 2.34%, which is 1 percentage points higher than the biotech industry average of 1.58%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 45.2% indicates that its dividend yield is sustainable for the long-term.

3. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.79%, which is the same as the biotech industry average of 1.58%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 34.4% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 1.15% in the last day, and up 6.25% over the last week. Sonnet Biotherapeutics Holdings was the among the top gainers in the biotechnology industry, gaining 86.46% yesterday.

Sonnet BioTherapeutics shares are trading higher after the company announced a newly formed entity through a business combination with Rorschach to launch a Crypto treasury reserve strategy.

What are the most undervalued biotech stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

1. Puma Biotechnology (NASDAQ:PBYI)


Puma Biotechnology (NASDAQ:PBYI) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 28 points higher than the biotech industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has dropped -5.74% in the past year. It has overperformed other stocks in the biotech industry by 64 percentage points.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 56 points higher than the biotech industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 2.06% in the past year. It has overperformed other stocks in the biotech industry by 72 percentage points.

3. United Therapeutics (NASDAQ:UTHR)


United Therapeutics (NASDAQ:UTHR) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

United Therapeutics has a valuation score of 43, which is 28 points higher than the biotech industry average of 15. It passed 3 out of 7 valuation due diligence checks.

United Therapeutics's stock has dropped -9.04% in the past year. It has overperformed other stocks in the biotech industry by 61 percentage points.

Are biotech stocks a good buy now?

53.23% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 92.36% over the next year.

2.34% of biotech stocks have a Zen Rating of A (Strong Buy), 3.61% of biotech stocks are rated B (Buy), 39.07% are rated C (Hold), 37.58% are rated D (Sell), and 17.41% are rated F (Strong Sell).

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is -158.64x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.